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Type 1 diabetes is considered as Th1 cell mediated auto-
immune disease and the suppression of Th1 cells or the activa-
tion of Th2 cells has been regarded as a plausible immunologic
intervention for the prevention of type 1 diabetogenesis in a
rodent model. CpG ODN is an immunostimulatory sequence
primarily present in bacterial DNA, viral DNA and BCG. CpG
ODN is conventionally classified as a Th1 cell activator, which
has been clinically applied to cancer, allergy and infectious
disease. Recently, there was a promising report of that CpG
ODN administration suppressed the development of type 1
diabetes in NOD mice by inducing Th2 cell mediated cytokine.
However, the antidiabetogenic effect of CpG ODN on NOD
mice is controversial. Thus, two studies were serially under-
taken with various kinds of CpG motif to find a more optimal
sequence and administration method. In the first study, CpG
ODN was vaccinated four times and pancreatic inflammation
and the quantity of serum insulin subsequently evaluated. In
the second study, the amounts of IFNγ and IL-4 in sera were
measured as representative cytokines of Th1 and Th2 cells,
respectively. As a result, vaccination or continuous injection
of CpG ODN failed to show a preventive effect on type 1
diabetogenesis in NOD mice. Structural differences of CpG
ODN also had no affect on the result. CpG ODN also
consistently showed affect on the pancreatic pathology. The
productions of IFN and IL-4 were detected only in the K γ
and D type CpG ODN administration groups. Comparison of
the two cytokines leads to the conclusion that CpG ODN
generated a Th1-weighted response in both study groups. It
was assumed that CpG ODN failed to produce Th2-weighted
cytokine milieu, which can overcome the genetically deter-
mined phenotype of NOD mice. Given these results, it was
concluded that the immunotherapeutic application of CpG
ODN on Type 1 diabetes had clear limitations.
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INTRODUCTION
Type 1 diabetes is a metabolic disease charac-
terized by hyperglycemia resulting from defects in
insulin secretion.
1,2 Type 1 diabetes is caused by
the progressive destruction of the insulin-produ-
cing beta cells through an autoimmune process.
3
It has been suggested that T helper 1 (Th1) cells
play a pathogenic role in the autoimmune de-
struction of beta cells, whereas T helper 2 (Th2)
cells play a nondestructive or preventive role in
type 1 diabetes due to the cytokine network they
produce.
4
Th1 cells secrete interleukin (IL)-2, interferon
(IFN) γ and tissue necrotic factor (TNF) α, and
predominantly support cell-mediated immunity.
Th2 cells secrete interleukins IL-4, IL-5, IL-10 and
IL-13, and primarily support humoral factor-medi-
ated immunity.
5 Based on the immunopatho-
genesis of type 1 diabetes, its immunotherapy has
been targeted to the immunosuppression of auto-
immune diseases, deletion of selective T cell sub-
sets and the induction of immune tolerance to islet
protein.
6-8 Numerous immunostimulatory pro-
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tocols have been designed to down-regulate the
development of T cell mediated autoimmune dia-
betes in rodent models, such as NOD (nonobese
diabetic) mice and BB (biobreeding) rats.
9-11 As an
effective immune modulator, BCG (Bacile Calmette-
Guerin) therapy has been well documented. How-
ever, the underlying immunologic mechanism of
BCG therapy in NOD mice is obscure.
12-14
Cytosine-phosphorous-Guanine (CpG) oligonu-
cleotide (ODN) is unmethylated base pairs present
in bacterial DNA, viral DNA and BCG.
15,16 CpG
ODN can be classified into the K and D types ac-
cording to the phosphorous backbone structure.
17
K type CpG ODN, with phosphorothioate back-
bones, triggers the maturation of plasmacytoid
dendritic cells and stimulate the production of im-
munoglobulin M and IL-6. Whereas, D type CpG
ODN, with a phosphodiester/phosphorothioate
backbone, triggers the maturation of antigen pres-
enting cells, preferentially inducing the secretion
of IFN α and IFN γ.
18,19 CpG ODN also can be
classified into the human and mouse types
according to the motif contained. Although there
is some cross-stimulation, the human or murine
type CpG ODN has an ability to activate human
or murine leukocytes, respectively.
16,20 Such a CpG
ODN is known to possess immunomodulatory
activity in the same way as other DNA vac-
cines.
15,16 Many experimental and clinical studies
have manifested the CpG motif activate Th1-like
immune response that can be harnessed as im-
mune therapies for cancer, allergies and infectious
diseases.
12,14,21,22 A recent report suggested CpG
ODN treatment significantly reduces the cumula-
tive incidence of diabetes in NOD mice.
23
However, the effect of CpG ODN on NOD mice
is still controversial. Besides, effective CpG
sequence, dose and administration methods have,
as yet, not been elucidated. To clarify these issues,
two studies were serially performed using dif-
ferent types of CpG ODN with different admin-
istration methods. Thus, this study was designed
to evaluate the effect of CpG ODN in reducing the
incidence of type 1 diabetes, and compare the
effects of species-specific CpG ODN on a rodent
model. Second, an attempt was made to evaluate
the effect of a continuous injection of CpG ODN
in reducing the development of type 1 diabetes
using different structural of CpG ODN types.
MATERIALS AND METHODS
NOD mice
Five week-old female NOD/LtJ mice, from
Jackson laboratory (Bar Harbor, ME, USA), were
bred in the animal laboratory of Wonju College of
Medicine, Yonsei University. In study one, 40
mice were divided into 3 groups. Twenty were
used as a control group and ten each were used
as mouse and human CpG ODN groups. In study
two, 40 mice were divided into 4 groups; ten each
were used as the control, K, D and Cohen's types
CpG ODN groups. NOD mice were maintained in
autoclaved cages, with sterile water. Rat diet Pico
5053 (Nutritional International Inc., Brentwood,
USA) was given as food. Food and water was
given without restrictions.
CpG preparation and injection
All the CpG ODNs were synthesized at Meta-
bion GmbH (Tlanegg/Martinsried, Germany). The
mouse and human type CpG ODN sequences
were as follows:
Mouse type CpG ODN: 5'-TCC ATG ACG
TTC CTG ACG TT-3'
Human type CpG ODN: 5'-TCG TCG TTT
TGT CGT TTT GTC GTT-3'
K, D and Cohen's type CpG ODN sequences
were as follows:
The K type CpG ODN was the same as that
of the mouse type CpG ODN: 5'-TCC ATG
ACG TTC CTG ACG TT-3'
D type CpG ODN: 5'-GGT GCA TCG ATG
CAG GGG GG-3'
Cohen's type CpG ODN: 5'-TCC ATA ACG
TTG CAA ACG TTT TG-3'
In study one, 100μL (10μg) of mouse type CpG
ODN, human type CpG ODN and normal saline
were subcutaneously vaccinated to each group in
the inguinal area. Vaccination was started during
the 5 week-old period, and repeated 7, 14 and 28
days later. In study two, 100 L (10 μ μg) of the K,
D and Cohen's CpG ODN types and normal
saline were given weekly from the 5 week-old to
the 24 week-old periods, as long as the NOD mice
were not diabetic.Limited Effect of CpG ODN
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Blood glucose
The blood glucose was measured using a Sure-
step glucometer (Lifescan, California, USA).
Animals were considered diabetic when two
consecutive measurements were greater than 13.75
mM/L (250 mg/dL), and sacrificed when consid-
ered diabetic. The mice were otherwise sacrificed
at 24 weeks of age in both studies.
Pancreatic histology
The pancreata were fixed with 4% parafor-
maldehyde (in 0.1 M phosphate buffer, pH 7.4)
and embedded in paraffin. The paraffin blocks
were serially sectioned into thickness of 5 μm and
three hematoxylin-eosin (H-E) stained slides made
for each block. Of the three H-E slides from each
block, the one with the most evenly distributed
islets with regard to size was selected. All the H-E
pancreata sections were evaluated for insulitis.
Pancreata were graded for insulitis on the basis of
the most severely involved islet in each pancreas.
Each pancreas was graded, and placed into one of
the following categories: Grade G0 when no infil-
trate was detected, G1 when peri-insulitis or an
intraislet infiltrate occupied < 25% of the islet, G2
when 25-50% of the islet was occupied by intra-
islet inflammatory cells and G3 when more than
50% of the islet was occupied by lymphocytes.
Insulin immunoassay
The serum insulin level was checked at the time
of sacrifice, and was measured in the fasting state
using a radioimmunoassay commercial Kit (Linco
Research Inc. St. Charles, Missouri, USA).
Cytokine assay
The IFN γ and IL-4 in the sera were mea-
sured at the time of sacrifice. Serum cytokines
were measured with an ELISA at the cytokine
bank, Chonbuk National University (Chonbuk,
Korea).
Statistical significance
Prism 3.0 (San Diego, USA) and SPSS10 (SPSS
Inc, Chicago, USA) were used for statistical an-
alyses. Kaplan-Meier, chi-square, one-way ANOVA
and repeated measures ANOVA tests were per-
formed to clarify the differences between the
experimental and control groups. P values be-
low 0.05 were considered statistically signifi-
cant.
RESULTS
Study One
CpG ODN vaccination is not protective on type 1
diabetogenesis in NOD mice
The diabetes free survival was 20% in the
mouse CpG ODN type, 10% in human CpG
ODN type and controls by 24 weeks of age. No
statistical difference was found between the
groups by the end or during the course of the
study (Fig. 1).
CpG ODN vaccination had no effect on the degree
of insulitis
No difference in insulitis was found between
the three groups. The mouse and human CpG
ODN types did not protect or aggravate insulitis
in NOD mice (Fig. 2).
Quantification of insulin
There were no statistical differences in levels of
insulin between the three groups (Fig. 3).
Fig. 1. Diabetes free survival of female NOD mice (Study
one).Byong Jun Lee, et al.
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Study Two
Continuous injection of CpG ODN is not protective
on type 1 diabetogenesis in NOD mice
The diabetes free survivals were 30, 20, 10 and
0% in the K, control, Cohen's and D CpG ODN
type groups, respectively, by the end of study
period. No statistical differences were observed
between the groups during the course of or at the
end of the study period (Fig. 4).
Serum cytokine concentration
IFN γ and IL-4 were measured as represen-
tative cytokines of Th1 and Th2 cells, respectively.
The concentrations of IFN γ and IL-4 were below
the limits of detection in the control and Cohen's
type CpG ODN groups. The mean values of IFN
γ and IL-4 were 0.235 and 0.045 ng/mL, and 0.052
and 0.004 ng/mL in the K and D type CpG ODN
groups, respectively (Fig. 5).
DISCUSSION
The two serially performed studies showed that
CpG ODN has no protective effect against type 1
diabetogenesis in NOD mice. Our rationale for
CpG ODN adoption in the rodent model of auto-
immune diabetes was based on the facts that BCG
may have the potential to suppress the develop-
ment of type 1 diabetes, or attenuate insulitis in
NOD mice.
12,24,25 Tokunaga demonstrated that the
effective fraction of BCG contain unmethylated
CpG ODN or CC-dinucleo-typed ODNs.
26 Now,
biologically active CpG ODN is commonly found
in bacterial, viral and vaccine plasmid DNA.
15,16
Despite much controversy relating to the Th1/Th2
balance in type 1 diabetes, Cohen's group re-
ported a promising result in the suppression of
type 1 diabetes in NOD mice with their CpG motif
by inducing more of IL-10 than IFN γ.
23 Bioactive
CpG ODN is classified into the K or D types, as
well as the mouse or human types. Cohen's motif
Fig. 2. Grade of insulitis in NOD mice.
Fig. 3. Insulin radioimmunoassay in NOD mice.
Fig. 4. Diabetes free survival of female NOD mice (Study
two).
Fig. 5. Comparative Th1 and Th2 cytokine releases in the
sera of the different CpG vaccinated mice types.Limited Effect of CpG ODN
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can be classified as non-K and non-D types.
In study one, species-specific K type CpG ODN
was used, although this kind of discrimination is
not absolute.
18,20 Before the in vivo administration
of human type CpG ODN, it was confirmed that
the human type CpG motif could stimulate innate
immune cells (mainly macrophage) in mice (un-
published data). The potency of the human type
CpG motif has been proved in a rodent model, as
it has cross-reactivity with mouse type CpG ODN.
In study two, the K, D and Cohen's type CpG
ODN were used. Theoretically, using K type CpG
ODN in NOD mice has the advantage of modu-
lating the autoimmune process due to its known
adjuvant potency, while the function of the D type
CpG motif is unclear. The Cohen's CpG motif was
adopted in our therapeutic protocol to see
whether it could reproduce the promising result,
as well as to evaluate the uniqueness of this se-
quence in causing different results.
As shown Fig. 1 and 4, the diabetes free sur-
vivals of NOD mice were not statistically signi-
ficant, and rather consistent with the natural in-
cidence of diabetes in NOD mice. The results of
Cohen's type CpG ODN, once assumed to be a
significant suppressor of type 1 diabetes, were no
better than any other CpG sequences. In study
one, the peri-insulitis and insulin concentration
were evaluated. Mouse and human CpG ODN
had no protective effects against inflammation of
pancreatic islet cells. Also, the quantity of serum
insulin was no different between the study
groups. In study two, IFN γ and IL-4 secretions
were only shown in the K and D type CpG ODN
groups, and the level of secretion was lower than
the limits of detection in the control and Cohen's
CpG ODN groups. Cohen's study explained their
result in terms of the Th1/Th2 balance, with
relatively a higher level of IL-10 to IFN γ causing
such a consequence. Although the vaccination
schedule, including the timing and dose, was the
same as in Cohen's study, in our first experiment
Cohen's CpG ODN failed to secrete Th1 and Th2
cell mediated cytokines. Thus, it is strange that in
both experiments and in nature the same results
are not reproducible. Our hypothesis is, "such a
discrepancy might be due to the difference in CpG
potencies". Cohen's CpG ODN may in fact not be
active enough to induce apoptosis of pathogenic
autoreactive T cells. Overall, it was assumed that
CpG ODN produced Th1-weighted cytokine mi-
lieu and the genetically determined phenotype of
NOD mice was not affected by CpG ODN as a
consequence.
Our findings indicate that CpG ODN can not
confer significant relief of type 1 diabetogenesis in
NOD mice. In conclusion, this result indicates that
CpG ODN has clear limitations when applied as
a immunotherapeutic for type 1 diabetes.
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